Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO, a biotechnology company, granted equity awards to two new employees under its 2022 Inducement Plan. The awards include restricted stock units and stock options, with vesting over a three-year period. The grants aim to incentivize and retain talent as part of the company's strategic growth.
INOVIO, a biotechnology company, will release their first quarter 2024 financial results on May 13, 2024. The company focuses on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. A live conference call and webcast will follow the release to discuss financial results and give a general business update.
INOVIO, a biotechnology company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, will participate in various investor conferences in May. Dr. Jacqueline Shea, President & CEO, will represent the company in fireside chats at The Citizens JMP Life Sciences Conference, RBC Capital Markets 2024 Global Healthcare Conference, and H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company aims to engage with investors through one-on-one meetings and webcasts available on their Investor Relations Events page.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.